CGEN - Compugen Ltd.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
2.65
+0.18 (+7.07%)
At close: 4:00PM EST

2.60 -0.05 (-1.89%)
Pre-Market: 4:42AM EST

Stock chart is not supported by your current browser
Previous Close2.47
Open2.55
Bid2.60 x 100
Ask2.65 x 200
Day's Range2.51 - 2.75
52 Week Range2.35 - 6.40
Volume211,804
Avg. Volume120,489
Market Cap135.532M
Beta2.18
PE Ratio (TTM)N/A
EPS (TTM)-0.67
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Trade prices are not sourced from all markets
  • Is It Too Late To Buy Compugen Ltd (CGEN)?
    Simply Wall St.7 days ago

    Is It Too Late To Buy Compugen Ltd (CGEN)?

    Compugen Ltd (NASDAQ:CGEN), a life sciences tools and services company based in Israel, received a lot of attention from a substantial price movement on the NasdaqGM in the over theRead More...

  • ACCESSWIRE15 days ago

    Compugen Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 10:00 AM Eastern Time. ...

  • Associated Press15 days ago

    Compugen reports 3Q loss

    On a per-share basis, the Holon, Israel-based company said it had a loss of 19 cents. The company's shares closed at $3. A year ago, they were trading at $5.95. _____ This story was generated by Automated ...

  • PR Newswire15 days ago

    Compugen Reports Third Quarter 2017 Results

    - Phase I Study for COM701 Expected to Start in 2018 - IND Application for COM902 Anticipated in 2019 HOLON, Israel , Nov. 7, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery ...

  • TheStreet.com16 days ago

    Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

    The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

  • PR Newswire20 days ago

    Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the initiation of a multi-year cancer immunotherapy research collaboration with Mount Sinai, under the direction of Miriam Merad, MD, PhD, Director of the Precision Immunology Institute and Co-Leader of the Cancer Immunology program and Mount Sinai Professor in Cancer Immunology at the Icahn School of Medicine at Mount Sinai in New York. Dr. Merad is a world-class leader in the field of myeloid biology for the development of novel cancer immunotherapies and is a member of Compugen's Scientific Advisory Board (SAB).

  • PR Newswire27 days ago

    Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it will present two posters with new data on COM701, the Company's first-in class immuno-oncology therapeutic antibody candidate targeting PVRIG, and COM902, the Company's immuno-oncology therapeutic antibody targeting TIGIT, at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8-12 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "Analysis of the TIGIT/PVRIG axis in human cancers to support indication selection and biomarkers for COM701 and COM902" (Poster no. P369) will be presented on Friday, November 10, 2017 at 12:30-2 pm and 6:30-8 pm ET.

  • PR Newswire28 days ago

    Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its third quarter financial results on Tuesday, November 7, 2017 before the U.S. financial markets open. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.

  • ACCESSWIRElast month

    Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032

    LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Compugen Ltd (NASDAQ: CGEN ), following which we have published ...

  • Company News For Oct 10, 2017
    Zackslast month

    Company News For Oct 10, 2017

    Companies in the news are: MZOR,CGEN,KTWO,AXTA

  • TheStreet.comlast month

    Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

    Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

  • PR Newswirelast month

    A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy

    HOLON, Israel, Oct. 9, 2017 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, disclosed new data demonstrating the potential of CGEN-15032 as a target for the development of first-in-class cancer therapy. CGEN-15032 is a novel myeloid and epithelial immuno-oncology target, which may serve as an immuno-suppressive target within the tumor microenvironment.

  • Compugen Ltd (CGEN): How Does It Impact Your Portfolio?
    Simply Wall St.2 months ago

    Compugen Ltd (CGEN): How Does It Impact Your Portfolio?

    If you are looking to invest in Compugen Ltd’s (NASDAQ:CGEN), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • PR Newswire4 months ago

    Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that CGEN-15032, a newly-disclosed novel myeloid and epithelial immuno-oncology target, will be the subject of both an oral and a poster presentation at the 3rd annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference taking place September 6-9, 2017 in Mainz/Frankfurt, Germany. The presentation titled "Computational discovery and experimental validation of CGEN-15032 as a novel target for cancer immunotherapy" is scheduled as part of the session titled "Other checkpoint blocking and immunomodulating antibodies," on Friday, September 8, 2:00-3:45 pm CEST.

  • ACCESSWIRE4 months ago

    Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen

    Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • Associated Press4 months ago

    Compugen reports 2Q loss

    The Holon, Israel-based company said it had a loss of 18 cents per share. The company's shares closed at $3.80. A year ago, they were trading at $6.91. _____ This story was generated by Automated Insights ...

  • PR Newswire4 months ago

    Compugen Welcomes Paul Sekhri as its New Chairman of the Board

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Board of Directors has appointed Paul Sekhri to serve as a Director and Chairman of the Board, effective October 2, 2017. As the new Chairman, Mr. Sekhri will succeed Martin Gerstel, who announced his intention to retire from this role in February of this year.

  • PR Newswire4 months ago

    Compugen Reports Second Quarter 2017 Results

    IND application for COM701 therapeutic antibody candidate for immuno-oncology expected to be filed towards the end of the first quarter of 2018 Compugen names Paul Sekhri as Chairman of the Board effective ...

  • PR Newswire4 months ago

    Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology

    HOLON, Israel, July 26, 2017 /PRNewswire/ -- Compugen Ltd. (CGEN), a therapeutic discovery company, announced today updates to its collaborative activities in immuno-oncology with Bayer. The agreement with Bayer AG involves the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022.

  • PR Newswire4 months ago

    Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate

    Compugen Ltd. (CGEN), a therapeutic discovery and development company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for COM701, the Company's lead immuno-oncology therapeutic antibody candidate. The patent was issued under the USPTO's pilot program providing early review for patent applications pertaining to cancer immunotherapy in support of the White House Cancer Moonshot program, and is one of less than a dozen patents granted under the program to date.

  • PR Newswire4 months ago

    Compugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET

    HOLON, Israel , July 24, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today that the Company will release its second quarter financial results on Wednesday, ...

  • PR Newswire6 months ago

    Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models

    Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today disclosed new data for its COM701 immuno-oncology therapeutic antibody candidate demonstrating potential for dual- and triple-combination therapy with antibodies targeting TIGIT and PD-1. In addition to monotherapy applications, this combination approach may expand the responsive cancer patient population, including those who are partially responsive or refractory to PD-1 inhibitors. Furthermore, recent expression data in human tumors point to the potential of COM701 to treat cancer patients for whom current PD-1 pathway inhibitors have shown limited efficacy.

  • PR Newswire6 months ago

    Compugen Provides Update on COM701 and Upcoming Presentations

    Compugen Ltd. (CGEN), a therapeutic discovery company, announced today that it anticipates a delay of several months in the submission of an investigational new drug application (IND) for COM701, Compugen's clinical candidate antibody targeting CGEN-15029/PVRIG. Previously the Company had disclosed an expectation of IND filing in Q4 of this year. The Company was recently informed by its manufacturing service provider for COM701 - a global contract development and manufacturing organization (CDMO) - that the batch of material they manufactured for Compugen's planned GLP (good laboratory practice) toxicity studies was contaminated during the manufacturing process.

  • PR Newswire6 months ago

    Compugen Announces Appointment of Dr. Michal Preminger to Board of Directors

    Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today announced that Michal Preminger, PhD, MBA, Executive Director at Harvard University Office of Technology Development's Harvard Medical School site, has been appointed a Director of Compugen by the Company's Board of Directors. Dr. Preminger brings to Compugen broad managerial and business experience focused on the pharma and biotech industries.

  • PR Newswire6 months ago

    Compugen to Present at Two Upcoming Investor Conferences in June

    HOLON, Israel, May 23, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer, will present ...